ClinicalTrials.gg
CompletedNCT02521207Updated Oct 28, 2015

Pilot Study of OXP001(2) and Brufen in Healthy Subjects

A Phase 1 interventional study of Ibuprofen in Gastroduodenal Erosions, sponsored by Oxford Pharmascience Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Oxford Pharmascience Ltd · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study will compare the study drug to an already marketed formulation of prescription strength ibuprofen (Brufen® the reference product) by looking at how the drug is taken up by the body and also by performing a specialist procedure called an endoscopy (or more specifically, a gastroscopy). The safety and tolerability of the study drug will also be assessed.

The study will consist of 2 parts involving up to 54 healthy male and female subjects. Subjects will be randomly assigned to receive either the study drug or reference product. Part 1 will be a cross over study in which up to 10 subjects will receive a single dose of 800 mg study drug OXP001 or Brufen® on Day 1, then a single dose of 800 mg study drug OXP001 or Brufen® on Day 4. Part 1 will assess bioavailability and involve an interim decision on progression to Part 2. In Part 2, up to 44 subjects will receive a dose of 800 mg OXP001 or Brufen® three times daily for 7 days in order to assess pharmacokinetics and stomach irritation using endoscopy.

02

Conditions studied

  • Gastroduodenal Erosions
03

In context

Lead sponsor

Oxford Pharmascience Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subject
  • Healthy, normal upper GI tract as indicated by no ulcers or erosions at baseline, as assessed by the gastroenterologist conducting the endoscopy (ie Lanza score of 0 in both the stomach and duodenum) (Part 2 only)
  • H. pylori negative

Exclusion criteria

Exclusion Criteria:

  • abnormal laboratory parameters
  • Any clinically significant diseases or conditions affecting the haematopoietic, cardiovascular, renal, hepatic, endocrine, pulmonary, central nervous, immunological, dermatological, GI or any other body system
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Part 1 OXP001

    OXP001 formulation containing 800mg ibuprofen single dose

    Drug: Ibuprofen

  • Active comparator
    Part 1 Ibuprofen control

    Ibuprofen control 800mg single dose

    Drug: Ibuprofen

  • Experimental
    Part 2 OXP001

    OXP001 formulation containing 800mg ibuprofen three times per day

    Drug: Ibuprofen

  • Experimental
    Part 2 Ibuprofen control

    Ibuprofen control 800mg three times per day

    Drug: Ibuprofen

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Comparison of Peak Plasma Concentration (Cmax)

    Time frame: Part 1; Day 1 and Day 4

  2. Part 2: Comparison of Average Lanza Score

    Time frame: Part 2; Day 8

  3. Part 2: Comparison of Average Number of Erosions

    Time frame: Day 8

  4. Part 1: Comparison of Area Under the Curve (AUC)

    Time frame: Part 1; Day 1 and Day 4

07

Study locations

1 site
  • Quotient Clinical Ltd
    Nottingham, Notts NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2015
First posted
Aug 13, 2015
Start
Jul 2015
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02521207
Lead sponsor
Oxford Pharmascience Ltd
Collaborators
Quotient Clinical
Responsible party
Sponsor
First posted
Aug 13, 2015
Start date
Jul 2015
Primary completion
Aug 2015
Completion
Sep 2015
Last update
Oct 28, 2015

Study contacts

Stuart Mair
principal investigator · Quotient Clinical Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion